Press Releases
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival
Bristol-Myers Squibb Company announced that a clinical trial -- known as study 024 -- of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Study 024 was designed to...
Press Releases
PharmaDiagnostics announces three new coupling methods for its SoPRano(TM) label-free platform
PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today the launch of three new methods for coupling proteins to the gold nanoparticles used with PharmaDiagnostics'Â SoPRano (TM)...
Press Releases
Provepharm receives favorable EMA Review of its methylthioninium chloride Proveblue
Provepharm, a start-up specialized in the development of pharmaceutical applications, announces today that, following a one-year centralized review procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CMPH) issued a favorable assessment of its methylthioninium chloride...
Press Releases
TxCell names François Meyer as CEO
TxCell SA, a biotechnology company developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need, announced the appointment of Dr. François Meyer as its chief executive officer. “The appointment of François...
Press Releases
Oxford Medical Diagnostics and V&F join forces in the field of mass spectrometry
Oxford Medical Diagnostics (OMD), the UK developer of breath based, medical diagnostic technology for the rapid, non-invasive, accurate and low-cost diagnosis and monitoring of metabolic and infectious diseases; and V&F Analyse- und Messtechnik GmbH (V&F), a provider of analytical...
Press Releases
Nycomed’s novel COPD therapy roflumilast receives FDA approval
Nycomed’s US partner Forest Laboratories, Inc.announced that DalirespTM (roflumilast) was approved by the US Food and Drug Administration (FDA) as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated...
Press Releases
PharmaDiagnostics appoints director of assay development
PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized instrumentation, announces today the appointment of Dr Sylviane Boucharens as director of assay development. Sylviane joins from Merck’s MSD site in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
